SCHEMBL6733795

SCHEMBL6733795

CCNC(=O)N1CC2CC(CN(CC(COc3ccc(C#N)cc3)NC(=O)N3CCOCC3)C2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.39
LMNA P02545 2/20 0.39
ADRB2 P07550 2/20 0.39
ADRB1 P08588 2/20 0.39
NFKB1 P19838 1/20 0.39
HIF1A Q16665 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NR1I2 O75469 1/20 0.39
ADRB3 P13945 1/20 0.39
PTGS2 P35354 1/20 0.39
KCNH2 Q12809 1/20 0.39
ACACB O00763 1/20 0.37
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
BLM P54132 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CHRNA7 P36544 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6737925 0.88 KCNH2 (0.40) KCNH2KMT2AMEN1CHRNA7HRH2
SCHEMBL6738637 0.88 KCNH2 (0.40) KDM4EKCNH2ACACBCHRNA7HRH2
SCHEMBL6737648 0.88 KCNH2 (0.40) KCNH2KMT2AMEN1CHRNA7HRH2
SCHEMBL6743533 0.88 KCNH2 (0.40) KCNH2KMT2AMEN1CHRNA7HRH2
SCHEMBL6739839 0.88 KCNH2 (0.40) KCNH2ACACBCHRNA7HRH2HRH1
SCHEMBL6737686 0.87 KCNH2 (0.39) KCNH2CHRNA7HRH2HRH1HRH3
SCHEMBL6738144 0.87 KCNH2 (0.39) KCNH2CHRNA7HRH2HRH1HRH3
SCHEMBL6743944 0.86 KCNH2 (0.38) ALDH1A1KCNH2ACACBCHRNA7HRH2
SCHEMBL6737542 0.84 KCNH2 (0.37) KCNH2CHRNA7HRH2HRH1
SCHEMBL6732773 0.83 KCNH2 (0.42) KCNH2CHRNA7HRH2HRH1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229900-A1 Bispidine compounds useful in the treatment of cardiac arrythmias ASTRAZENECA AB (SE) 2004-11-18 US disclosed
EP-1192157-A1 BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2002-04-03 EP disclosed
WO-2000077000-A1 NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229900-A1 Bispidine compounds useful in the treatment of cardiac arrythmias ADRA1B, ADRB2, ADRA1D ALDH1A1 790/4885KDM4E 4541/4885HTT 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.